Edwards Lifesciences Corp Investor Update at TCT Transcript
Here in Boston, and we appreciate you all spending time with us as well as for those of you online. We've got a great session, I think, lined up this evening. And it's really the reflection of a lot of great news that we had over the course of this week. On Monday, the FDA-approved SAPIEN 3 Ultra with RESILIA. On Thursday, we got FDA approval for PASCAL to treat DMR patients here in the U.S.
And today, we presented, I think, some pretty compelling data at the conference itself. So that's going to be kind of the flow of the evening session.
I'll start by calling your attention to the forward-looking statement. We will, as we do, and these events have a tendency to make forward-looking statements. I would just call your attention to this. It's also available on our website, so please familiarize yourself with it. This is the agenda itself. So I mentioned it's about an hour session, we're going to break it up into 2 parts.
The first portion of the session, you can see we've gathered some of our TMTT leaders here on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
